Weems Pennington, MD
Cardiovascular Disease · Aiken, SCNPI 1215027263
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 196 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Boston Scientific at 30.5% of the total. That places this record below the midpoint for cardiovascular disease clinicians in SC, where the typical reported total is $3,855.
Across 196 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Novartis$332
- Pfizer$276
- Abbott$261
- Abiomed$166
- E.r. Squibb & Sons, L.L.C.$152
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,88398%
- Education$992%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 46 | $1,216 |
| Novartis | 19 | $332 |
| Pfizer | 17 | $276 |
| Abbott | 13 | $261 |
| Abiomed | 4 | $166 |
| E.r. Squibb & Sons, L.L.C. | 7 | $152 |
| AstraZeneca | 5 | $149 |
| Medtronic(2 entities) | 7 | $135 |
| Cardiovascular Systems Inc. | 10 | $131 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $125 |
| Amgen | 10 | $124 |
| Inari Medical, Inc. | 3 | $110 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| Johnson & Johnson | 5 | $62 |
| Astellas Pharma US Inc | 3 | $56 |
| Stryker | 3 | $54 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $51 |
| Penumbra, Inc. | 3 | $46 |
| Daiichi Sankyo Inc. | 2 | $44 |
| Novo Nordisk | 2 | $40 |
| Veryan Medical Incorporated | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Shockwave Medical, Inc | 1 | $32 |
| Boehringer Ingelheim | 2 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| W. L. Gore & Associates, Inc. | 1 | $25 |
| Vital Connect, Inc | 1 | $21 |
| Cardiva Medical, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $18 |
| Biotronik Inc. | 1 | $17 |
| Getinge USA Sales, LLC | 1 | $17 |
| Bayer | 1 | $17 |
| Solventum Corporation | 1 | $17 |
| Lundbeck LLC | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| Itamar Medical Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Watchman$129
How this compares
$3,982 in reported general payments places this provider in the 50th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 698 | $679,363 |
| EntrestoSacubitril/Valsartan | 197 | $208,320 |
| XareltoRivaroxaban | 140 | $127,815 |
| Repatha SureclickEvolocumab | 53 | $51,803 |
| JardianceEmpagliflozin | 48 | $41,142 |
| MultaqDronedarone Hcl | 28 | $36,876 |
| BrilintaTicagrelor | 24 | $20,209 |
| FarxigaDapagliflozin Propanediol | 21 | $15,805 |
| Ranolazine ErRanolazine | 91 | $9,014 |
| Metoprolol Succinate | 379 | $5,838 |
| ClopidogrelClopidogrel Bisulfate | 357 | $4,673 |
| Atorvastatin Calcium | 372 | $3,417 |
| Icosapent Ethyl | 13 | $3,380 |
| Repatha SyringeEvolocumab | 12 | $3,185 |
| Carvedilol | 300 | $2,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $276 | $679,363698 claims |
| NovartisEntresto | $332 | $208,320197 claims |
| Johnson & JohnsonXarelto | $62 | $127,815140 claims |
| Boehringer IngelheimJardiance | $26 | $41,14248 claims |
| Sanofi-aventis U.S. LLCMultaq | $77 | $36,87628 claims |
| AstraZenecaBrilinta, Farxiga | $149 | $36,01545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 257 cardiovascular disease providers in South Carolina.
Other cardiovascular disease in Aiken
- Gregory EavesAiken$65K
- Robert BiedermanCharleston$775K
- Darren SidneyNorth Charleston$129K
- Priyanka BhattacharyaCharleston$107K
- Gregory SanGreenville$88K
- David McNeelyGreenville$78K
- James SmithCharleston$64K
- Christopher SalmonGreenville$54K
- Ricky HendersonAnderson$52K
- Geetha PintoCharleston$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.